| Autor: |
Hofstetter G; Department of Pathology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Grech C; Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.; Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Pils D; Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Pammer J; Department of Pathology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Neudert B; Department of Pathology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Pötsch N; Department of Radiology and Nuclear Medicine, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Baltzer P; Department of Radiology and Nuclear Medicine, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Traub-Weidinger T; Department of Radiology and Nuclear Medicine, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Seebacher V; Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria., Aust S; Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. |
| Abstrakt: |
Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to further studies investigating the use of imaging and therapeutic modalities targeting PSMA. Eighty patients with advanced stage high-grade serous ovarian cancers were included. Using immunohistochemistry, PSMA and CD31, a marker for endothelial cells, were examined in whole tissue sections. Percentage and intensity of PSMA expression were determined in the neovasculature. Expression levels were correlated with clinicopathological parameters and survival. Low (≤10%), medium (20-80%), and high (≥90%) PSMA expression was found in 14, 46, and 20 ovarian cancer samples, respectively. PSMA expression was confined to tumor-associated neovasculature and significantly correlated with progression-free (HR 2.24, 95% CI 1.32-3.82, p = 0.003) and overall survival (HR 2.73, 95% CI 1.41-5.29, p = 0.003) in multivariate models, considering age, FIGO stage, and residual disease. This is the first study showing a clinical relevance for PSMA in patients with ovarian cancer. PSMA was detected in the vast majority of cancer samples and showed an impact on survival. |
